Dr. Roger Packer

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as an Elite provider by MediFind in the treatment of Schwannomatosis. Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.

Carlos Romo, M.D., is a neuro-oncologist in Baltimore, Maryland. Dr. Romo specializes in the diagnosis and treatment of brain tumors, including glioblastoma, astrocytomas, oligodendrogliomas, neurofibromas, and schwannomas among others. Dr. Romo earned his medical degree from the School of Medicine and Health Sciences at Tecnológico de Monterrey in Mexico and completed his Neurology residency at the University of Arkansas for Medical Sciences, where he served as chief resident. He then completed a Neuro-oncology clinical and research fellowship in a joint program between The Johns Hopkins University and the National Institutes of Health. Dr. Romo additionally trained as a clinical pharmacology fellow at The Johns Hopkins University and completed training on clinical cancer research at the University of Texas MD Anderson Cancer Center. In his research, Dr. Romo studies drug pharmacokinetics and the blood-brain barrier, and investigates better ways to reach tumors in the central nervous system. Dr. Romo also studies treatments for patient with neurofibromatosis. In addition to patient care and research, Dr. Romo teaches and mentors medical and undergraduate students to help develop a future generation of neurologists. Dr. Romo is rated as a Distinguished provider by MediFind in the treatment of Schwannomatosis. His top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Schwannomatosis, and Astrocytoma.

Dr. Ahmet Hoke is Professor of Neurology and Neuroscience, W. W. Smith Charitable Trust Professor of Neuroimmunology at Johns Hopkins School of Medicine, Director of the Daniel B. Drachman Division of Neuromuscular Diseases and Director of the Merkin Peripheral Neuropathy and Nerve Regeneration Center at Johns Hopkins University School of Medicine. He completed his medical training at Hacettepe University School of Medicine in Ankara, Turkey followed by his PhD studies in developmental neuroscience at Case Western Reserve University in Cleveland, Ohio, and neurology residency at Johns Hopkins Hospital. After completing his neuromuscular training at University of Calgary, Canada, he returned to Johns Hopkins University as faculty and rose through the ranks. He is the recipient of several awards including Derek Denny Brown Young Neurological Scholar Award (2005) and Wolfe Neuropathy Research prize (2018) given by the American Neurological Association, Myung Memorial Lecture Award (2017) by the Korean Neurological Association, Nejat Eczacibasi Medical Scientist Award (2019) by the Eczacibasi Foundation, Turkey, and Alan J. Gebhart Prize in Excellence in Neuropathy Research (2022) by the Peripheral Nerve Society. He is an Ex-Officio member of the Board of Directors of the American Neurological Association, and Vice-President of the Toxic Neuropathy Consortium. He serves on several editorial boards and is the Editor-in-Chief of Annals of Clinical and Translational Neurology. Dr. Hoke is rated as a Distinguished provider by MediFind in the treatment of Schwannomatosis. His top areas of expertise are Wallerian Degeneration, Peripheral Neuropathy, Tomaculous Neuropathy, Spinal Muscular Atrophy with Arthrogryposis, and Prostatectomy.